

प्र. का. लेखा एवं लेखा परीक्षा विभाग "शेयर कक्ष",बैंक हाऊस, प्रथम तल, 21, राजेन्द्रा प्लेस, नई दिल्ली-110 008 H.O. Accounts & Audit Department "Shares Cell", Bank House, 1st Floor, 21, Rajendra Place, New Delhi - 110008

Phone: 011-25782926, 25812922, 25817353, 25728930, Email:complianceofficer@psb.co.in

दिनांक /Dated:....

Ref: PSB/HO/Shares Cell/

/2018-19

April 19, 2018

To.

Bombay Stock Exchange Limited, Department of Corporate Services, 25th floor, Phiroze Jeejeebhoy Towers, Dalal Street, Fort, Mumbai - 400 001.

SCRIP ID: PSB

SCRIP CODE: 533295

National Stock Exchange of India Ltd.,

Exchange Plaza, C - 1, Block - G, Bandra Kurla Complex, Bandra (East),

Mumbai - 400 051.

SYMBOL: PSB SERIES: EQ

Dear Sir,

Reg: Clarification on News Item appearing in NDTV - Sources dated 18-Apr-2018, titled "CBI Files Case Against Three Directors in Rs. 621-Crore Fraud Involving Punjab And

With reference to media reports in the subject account, we submit as under:

The Bank hereby clarifies that the subject account of M/s Surya Pharmaceuticals Pvt Ltd is an old case of Consortium advance with SBI as Consortium leader. The account turned NPA in 2011 with book outstanding of Rs.169 crore with our bank and 100% provision has already been made in the account.

SBI, the consortium leader has already filed a complaint with CBI for its own exposure to the party. After taking consent of remaining members of consortium, Punjab & Sind Bank being second largest lender in the account also filed a criminal complaint on 11.04.2018. The exposure of Rs.621 crore mentioned in section of press is for consortium (excluding SBI) and share of Punjab & Sind Bank is Rs

Further, as per extant procedures, the Bank reported the fraud to RBI. The case has now been registered as per procedures. Since 100% exposure in this account has already been provided, as such there will be no additional impact on profitability of the Bank.

Yours faithfully,

[Ajit Singh Ahuja] Company Secretary